Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Therapeutic drug monitoring of lacosamide among children: is it helpful?

View through CrossRef
Objective: This study aimed to investigate the efficacy and tolerability of Lacosamide (LCM) in a pediatric population with epilepsy using LCM serum concentration and its correlation to the age of the participants and the dosage of the drug.Methods: Demographic and clinical data were collected from the medical records of children with epilepsy treated with LCM at Shamir Medical Center between February 2019 to September 2021, in whom medication blood levels were measured. Trough serum LCM concentration was measured in the biochemical laboratory using High-Performance Liquid Chromatography (HPLC) and correlated with the administered weight-based medication dosing and clinical report.Results: Forty-two children aged 10.43 ± 5.13 years (range: 1–18) were included in the study. The average daily dose of LCM was 306.62 ± 133.20 mg (range: 100–600). The average number of seizures per day was 3.53 ± 7.25 compared to 0.87 ± 1.40 before and after LCM treatment, respectively. The mean LCM serum concentration was 6.74 ± 3.27 mg/L. No statistically significant association was found between LCM serum levels and the clinical response (p = 0.58), as well as the correlation between LCM dosage and the change in seizure rate (p = 0.30). Our study did not find a correlation between LCM serum concentration and LCM dosage and the gender of the participants: males (n = 17) females (n = 23) (p = 0.31 and p = 0.94, respectively). A positive trend was found between age and LCM serum concentrations (r = 0.26, p = 0.09).Conclusion: Based on the data that has been obtained from our study, it appears that therapeutic drug monitoring for LCM may not be necessary. Nonetheless, further research in this area is needed in the light of the relatively small sample size of the study.
Title: Therapeutic drug monitoring of lacosamide among children: is it helpful?
Description:
Objective: This study aimed to investigate the efficacy and tolerability of Lacosamide (LCM) in a pediatric population with epilepsy using LCM serum concentration and its correlation to the age of the participants and the dosage of the drug.
Methods: Demographic and clinical data were collected from the medical records of children with epilepsy treated with LCM at Shamir Medical Center between February 2019 to September 2021, in whom medication blood levels were measured.
Trough serum LCM concentration was measured in the biochemical laboratory using High-Performance Liquid Chromatography (HPLC) and correlated with the administered weight-based medication dosing and clinical report.
Results: Forty-two children aged 10.
43 ± 5.
13 years (range: 1–18) were included in the study.
The average daily dose of LCM was 306.
62 ± 133.
20 mg (range: 100–600).
The average number of seizures per day was 3.
53 ± 7.
25 compared to 0.
87 ± 1.
40 before and after LCM treatment, respectively.
The mean LCM serum concentration was 6.
74 ± 3.
27 mg/L.
No statistically significant association was found between LCM serum levels and the clinical response (p = 0.
58), as well as the correlation between LCM dosage and the change in seizure rate (p = 0.
30).
Our study did not find a correlation between LCM serum concentration and LCM dosage and the gender of the participants: males (n = 17) females (n = 23) (p = 0.
31 and p = 0.
94, respectively).
A positive trend was found between age and LCM serum concentrations (r = 0.
26, p = 0.
09).
Conclusion: Based on the data that has been obtained from our study, it appears that therapeutic drug monitoring for LCM may not be necessary.
Nonetheless, further research in this area is needed in the light of the relatively small sample size of the study.

Related Results

Role of Lacosamide in Diabetic Neuropathy: An Experience at Tertiary Care Hospital in Rural Sindh
Role of Lacosamide in Diabetic Neuropathy: An Experience at Tertiary Care Hospital in Rural Sindh
Background: Lacosamide is a relatively newer drug for treatment of chronic diabetic painful neuropathy (CDPN). Objective: To analyse the effectiveness and safety of lacosamide in p...
Efficacy of Lacosamide in Patients with Diabetic Neuropathy
Efficacy of Lacosamide in Patients with Diabetic Neuropathy
Objective: To compare the efficacy of lacosamide versus placebo in patients with diabetic neuropathy in terms of reduction of the mean pain score. Methodology: This randomized con...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Being Jacob: Young Children, Automedial Subjectivity, and Child Social Media Influencers
Being Jacob: Young Children, Automedial Subjectivity, and Child Social Media Influencers
Introduction Children are not only born digital, they are fashioned toward a lifestyle that needs them to be digital all the time (Palfrey and Gasser). They click, tap, save, circu...
Lacosamide‐induced personality changes: An unexpected adverse effect
Lacosamide‐induced personality changes: An unexpected adverse effect
AbstractObjectivesTo describe an ‘unexpected’ case of abrupt personality following the introduction of lacosamide.MethodsA description of an 82‐year‐old male receiving neurological...
Daniela Fenu Foerch: interview by Márcia Fusaro and Ana Maria Haddad Baptista
Daniela Fenu Foerch: interview by Márcia Fusaro and Ana Maria Haddad Baptista
EccoS Journal: Dr Foerch thank you very much for this interview. Could you start telling us about your professional background and what the WeFEEL project is? Daniela Fenu Foerch:...
Lacosamide: a new therapeutic option for refractory trigeminal neuralgia
Lacosamide: a new therapeutic option for refractory trigeminal neuralgia
Case Presentation: A 60-year-old previously healthy female patient presented, approximately 6 months earlier, with sudden, intermittent, shock-like pain of very high intensity in t...

Back to Top